Target's General Information
Target ID T20178
Target Name Tumor necrosis factor (TNF)
Synonyms Tumour necrosis factor alpha; Tumour necrosis factor; Tumor necrosis factor ligand superfamily member 2; TNFalpha; TNFSF2; TNFA; TNF-alpha; TNF-a; TNF alpha; Cachectin
Target Type Successful
Gene Name TNF
Biochemical Class Cytokine: tumor necrosis factor
UniProt ID TNFA_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Sepsis
Example drug Segard Discontinued in Phase 3 [1], [2], [3]
Tissue Whole blood
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.16
Z-score: 0.42
P-value: 1.82E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Myeloma
Example drug Lenalidomide Approved [2], [3], [4], [5], [6], [7]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.14
Z-score: -0.65
P-value: 1.66E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Psoriasis
Example drug Infliximab Approved [8], [9], [10], [2], [3]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.42
Z-score: 1.18
P-value: 1.24E-17
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.2
Z-score: -0.39
P-value: 1.95E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug Adalimumab Approved [11], [12], [2], [3]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.07
Z-score: -0.16
P-value: 7.38E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Ulcerative colitis
Example drug Infliximab Approved [8], [9], [10], [2], [3]
Tissue Colon mucosal tissue
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.15
Z-score: 0.7
P-value: 7.91E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Esophagal cancer
Example drug Golnerminogene pradenovac Phase 3 [13], [2], [3]
Tissue Esophagus
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.21
Z-score: -0.39
P-value: 2.80E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Osteoarthritis
Example drug DLX-105 Phase 2 [14], [2], [3]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.02
Z-score: 0.09
P-value: 4.93E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Idiopathic pulmonary fibrosis
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.06
Z-score: -0.16
P-value: 8.64E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Lateral sclerosis
Tissue Cervical spinal cord
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.05
Z-score: 0.27
P-value: 8.51E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002771)
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
REF 5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
REF 6 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
REF 7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
REF 9 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
REF 10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
REF 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4860).
REF 12 Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66.
REF 13 ClinicalTrials.gov (NCT00051467) A Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. U.S. National Institutes of Health.
REF 14 ClinicalTrials.gov (NCT01624376) Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.